Skip to main content
Cambrex logo

Cambrex — Investor Relations & Filings

Ticker · CBM ISIN · US1320111073 LEI · 4Q9DLX2VIFGJMOYJ4Y35 US Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country US United States of America
Listing US CBM

About Cambrex

https://www.cambrex.com

Cambrex is a global contract development and manufacturing organization (CDMO) that provides comprehensive services across the entire drug development lifecycle. The company partners with biotech and pharmaceutical firms, offering expertise in three core areas: drug substance, drug product, and analytical services. Drug substance capabilities include the development and manufacturing of Active Pharmaceutical Ingredients (APIs), covering custom, generic, and peptide-based therapeutics from preclinical through commercial stages. Drug product services focus on formulation development and manufacturing for clinical trials. A full suite of analytical services supports these activities, encompassing IND-enabling studies, solid-state chemistry, stability storage, and quality control testing. Cambrex supports clients from early-phase development to late-stage clinical trials and commercialization, emphasizing a collaborative, scientist-led approach to manage complex programs.

Recent filings

Filing Released Lang Actions
Cambrex Advances US and European Expansions
Regulatory Filings Classification · 32% confidence The text is a corporate press release announcing operational expansions (new API manufacturing plants and R&D facilities). It contains no financial results (so not an Earnings Release or Management Discussion), no annual/interim report content, no board changes, no share issues, no dividends, no M&A, and no investor presentation slides. It is essentially a standard corporate news announcement that does not neatly fit any specific report category, so the fallback classification is Regulatory Filings (RNS).
2026-03-23 English
Cambrex gibt Cornell-Professor Song Lin als Preistrager des Snapdragon-Preises 2025 fur Innovation in der Chemietechnik bekannt
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing the recipient of the 'Snapdragon Prize for Innovation in Chemistry Technology 2025'. It does not contain financial results, regulatory filings, or governance disclosures. As it is a general corporate announcement that does not fit into the specific categories provided, it falls under the fallback category of Regulatory Filings (RNS).
2026-02-19 German
Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing a $120 million capital investment by Cambrex to expand its API manufacturing facilities. It details the strategic rationale, the specific site (Charles City, Iowa), and the impact on the company's capacity. Since this document describes a specific capital expenditure and financing-related expansion project rather than a recurring financial report or a regulatory filing, it falls under the 'Capital/Financing Update' category.
2025-10-22 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.